Last reviewed · How we verify

Remifentanil fixed

Erasme University Hospital · FDA-approved active Small molecule

Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation.

Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation. Used for Intravenous analgesia and sedation during general anesthesia and monitored anesthesia care, Acute postoperative pain management.

At a glance

Generic nameRemifentanil fixed
SponsorErasme University Hospital
Drug classOpioid agonist
TargetMu (μ) opioid receptor
ModalitySmall molecule
Therapeutic areaAnesthesia / Analgesia
PhaseFDA-approved

Mechanism of action

Remifentanil activates mu opioid receptors, which inhibit pain signal transmission and produce sedative effects. It is characterized by rapid onset and offset due to metabolism by non-specific plasma and tissue esterases, making it suitable for short procedures and intravenous anesthesia. The drug is commonly used in perioperative settings where quick reversibility is clinically advantageous.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: